Chemo plus targeted radiation versus chemo alone for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (not lymphoma) confirmed by pathology (biopsy/surgery results).
- Your liver tumors can be treated fully with the radiation plan, and each tumor setup fits the study size limits (no tumor over 25 cm).
- You have 5 or fewer measurable liver lesions, checked on a contrast CT or MRI within the last 90 days.
- Your cancer can’t be removed by surgery (it’s considered medically or surgically unresectable).
- You can have standard blood counts and liver lab results (for example, platelets, bilirubin, and INR must be in acceptable ranges).
- You’re 18 or older, can give consent, and have a life expectancy of more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a combination of two drugs (bevacizumab and sintilimab) versus a standard procedure (TACE) for people with intermediate-stage liver cancer that is too large or widespread for surgery. The goal is to see if the drug combination works better at controlling the cancer.
This trial compares two treatment approaches for large hepatocellular carcinoma (HCC), a type of liver cancer: stereotactic body radiation therapy (SBRT) alone versus SBRT plus TACE, a catheter-based chemo treatment. It may help decide which approach works better for controlling the tumor when surgery isn’t a good option.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.